Oncology Precision Medicine Market, By Component (Therapeutics (Targeted therapies, Targeted biologics, Precision immuno-oncology, Cell & gene therapies, Radiotheranostics / targeted radionuclide therapies, Combination regimens), Diagnostics / Testing (Companion diagnostics (CDx), Complementary diagnostics, Comprehensive genomic profiling (CGP) panels, Minimal residual disease (MRD) testing, and Pharmacogenomics (PGx) relevant to oncology regimens), Informatics & Decision Support (Clinical decision support (CDS) / treatment matching engines, Variant interpretation & annotation platforms, Molecular tumor board (MTB) enablement software, and Data integration (EHR/LIS/omics) & interoperability tools, and Services (Sample logistics, biobanking, and pre-analytics services, Bioinformatics services (pipeline, interpretation, reporting), Clinical trial matching services, Real-world evidence (RWE) and outcomes analytics, and Contract research / companion diagnostic development services)), , By Care Pathway Stage (Risk Assessment & Screening, Diagnosis & Tumor Classification, Therapy Selection, Treatment Monitoring (Response Monitoring, Resistance Emergence Detection, Dose/Therapy Optimization), Recurrence Surveillance / MRD, and Clinical Trial Enrolment & Matching), By Technology (Genomics (Next-generation sequencing (NGS) (Targeted panels, Whole exome sequencing (WES), and Whole genome sequencing (WGS)), PCR / qPCR / ddPCR, Sanger sequencing (confirmatory)), Transcriptomics (RNA sequencing (RNA-seq), Gene expression profiling / signatures), Proteomics / Protein biomarkers, (Immunohistochemistry (IHC), Mass spectrometry–based proteomics (select settings)), Cytogenetics & Structural Variation (FISH, Karyotyping (certain hematologic cancers), Epigenetics (DNA methylation profiling (select tumors), Liquid biopsy technologies (ctDNA / cfDNA, CTCs, Exosomes / extracellular vesicles (emerging)), Single-cell & spatial, (Single-cell sequencing (scRNA/scDNA), Spatial transcriptomics / multiplex imaging)), By Biomarker Type (Genetic biomarkers (Single nucleotide variants (SNVs), Indels, Copy number variations (CNVs), Gene fusions / rearrangements, Germline variants (hereditary cancer)), Genomic signatures / global markers, Tumor mutational burden (TMB), Microsatellite instability (MSI), Homologous recombination deficiency (HRD)), Expression / protein markers, (Receptor status, ligand expression, immune markers (e.g., checkpoint pathway expression classes)), Epigenetic biomarkers, (Methylation signatures), MRD biomarkers, (Personalized tumor-informed MRD, Tumor-naïve MRD panels)), By Sample Type (Tissue-based (FFPE tissue, Fresh frozen tissue, Core needle biopsy / surgical specimens), Blood-based (liquid biopsy) (Plasma (ctDNA/cfDNA), Whole blood (CTCs, RNA), Other biofluids (Urine, saliva, CSF (indication-dependent)), Cytology samples (FNA, smears (select workflows)), By End User (Hospitals & cancer centers, Diagnostic laboratories (Clinical pathology labs, Molecular/genetic labs), Academic & research institutes, Pharmaceutical & biotech companies, CROs / clinical trial networks, and Payers / HTA bodies), By Cancer Type (Solid Tumors, Hematologic Malignancies, and Rare Cancers / Tumor-agnostic Segments (Tumor-agnostic biomarker-defined populations)), By Reimbursement & Access Channel (Public Reimbursement, Private Reimbursement, Out-of-pocket / Self-pay, Hybrid coverage models, Patient Assistance / Access Programs, and Clinical trial–funded Testing), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East and Africa) - Growth Trends and Forecasts (2026-2033)